Consortium Member of the Month

Our consortium member of the month for the month of February goes to Briant Fruth from Mayo Clinic!

Briant Fruth

Principal Statistical Programmer

Briant has been an invaluable member of our statistical team at Mayo Clinic. His contributions have been pivotal in the statistical analysis efforts of the MPN-RC 106 specimen bank. He has expertly addressed various queries, seamlessly integrated biomarker data, and conducted comprehensive cytokine statistical analyses.

Written by: Amylou C. Dueck, PhD

Nominated by: Victoria Rivera

Briant, thank you so much for all of the phenomenal work you have done for the consortium.

Keep up the great work!

MPN-RC Monthly Publication

Title: Sequential treatment with ruxolitinib and imetelstat effectively depletes myelofibrosis hematopoietic stem and progenitor cells

Author(s): Xiaoli Wang, Andrew Davis, Cing Siang Hu, Fei Huang, Sophia Jiang, John Mascarenhas, and Ronald Hoffman

Full Article

We are HIRING!

Mount Sinai Health System is looking to hire three Senior Scientists. Use the links below for more information and to apply for the position(s).

Apply HERE!

Apply HERE!

ASH Conference 2025

(Left to Right: Gaby Bello, Carly Sullivan, Ashley Yu) The Mount Sinai group from the MPN Research Consortium attended the American Society of Hematology 2025 Conference in Orlando, Florida.
Dr. Xiaoli Wang presents her ASH abstract “Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells”. View the abstract here!
Dr. Andrew Kuykendall presents his ASH abstract “A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1”. View the abstract here!
(Left to Right: Md. Babu Mia, Noushin Rahnamay, Dr. Bridget Marcellino, and Dr. Raajit Rampal) The Mount Sinai and Memorial Sloan Kettering group from the MPN Research Consortium attended the American Society of Hematology 2025 Conference in Orlando, Florida.

ASH Abstracts

Marina Kremyanskaya, MD,PhD

Phase II study of reparixin in patients with myelofibrosis. myeloproliferative neoplasms research consortium (MPN-RC) 120 trial

Full ASH Abstract
John Crispino, PhD,MBA

Menin inhibition as a new therapeutic option for the myeloproliferative neoplasms

Full Ash Abstract
John Mascarenhas, MD

Bone marrow adipocytes (BMA) as a novel biomarker of molecular response in patients with essential thrombocythemia (ET) and polycythemia vera (PV) treated with pegylated interferon alfa-2A

Full ASH Abstract
Andrew Kuykendall, MD

A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1

Full Ash Abstract
Min Lu, MD,PhD

Myelofibrosis stem cell fitness requires microenvironmental cell interactions

Full ASH Abstract
Xiaoli Wang, MD,PhD

Therapy resistance and disease relapse in patients with MPN-blast phase are associated with clonal evolution and transcriptomic changes in MPN- blast phase stem cells

Full Ash Abstract
MD Babu Mia, PhD

Single cell transcriptional profiling reveals distinct subsets of human megakaryocytes in myelofibrosis

Full ASH Abstract